updated 1/12/2011 7:15:35 AM ET 2011-01-12T12:15:35

DALLAS, Jan. 12, 2011 (GLOBE NEWSWIRE) -- MicroStockProfit.com announces an investment report featuring Genta Inc. (OTCBB:GNTA). The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

The full report is available at: www.microstockprofit.com/lp/GNTA

Genta (OTCBB:GNTA) is a biopharmaceutical company engaged in pharmaceutical research and development. It is dedicated to the identification, development and commercialization of novel drugs for the treatment of cancer and related diseases. The Company's research portfolio consists of two major programs: "DNA/RNA Medicines" (which includes its lead oncology drug, Genasense®); and "Small Molecules" (which includes its marketed product, Ganite®, and tesetaxel and oral gallium-containing compounds). 

For only $19 a month, you can sign up for our real-time stock alert service.  Click here to join now: http://www.pennystocklive.com/premium-membership/

In the report, the analyst notes:

"GNTA recently provided an update of its research and development activities in conjunction with its presentation at this year's Biotech Showcase in San Francisco.

"GNTA said it has initiated and completed more randomized phase III trials with Genasense than any other company. It also said it has completed accrual in two randomized phase III trials of Genasense in patients with advanced melanoma."

To read the entire report visit: www.microstockprofit.com/lp/GNTA

See what investors are saying about GNTA at http://www.stockhideout.com

Get breaking news on GNTA at http://thestockmarketwatch.com/

MicroStockProfit.com is a small-cap research and investment commentary provider. MicroStockProfit.com strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on MicroStockProfit please visit: http://www.microstockprofit.com

MicroStockProfit.com Disclosure

MicroStockProfit.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. MicroStockProfit.com is a Web site wholly owned by BlueWave Advisors, LLC. Neither MicroStockProfit.com nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. Please read our report and visit our Web site, MicroStockProfit.com, for complete risks and disclosures.

CONTACT: Brian Johnson
         info@microstockprofit.com
         1-888-307-2850

© Copyright 2012, GlobeNewswire, Inc. All Rights Reserved

Discuss:

Discussion comments

,

Most active discussions

  1. votes comments
  2. votes comments
  3. votes comments
  4. votes comments

Data: Latest rates in the US

Home equity rates View rates in your area
Home equity type Today +/- Chart
$30K HELOC FICO 4.93%
$30K home equity loan FICO 5.20%
$75K home equity loan FICO 4.58%
Credit card rates View more rates
Card type Today +/- Last Week
Low Interest Cards 13.42%
13.40%
Cash Back Cards 17.92%
17.91%
Rewards Cards 17.13%
17.11%
Source: Bankrate.com